• linkedin
  • Increase Font
  • Sharebar

    9 Newly Approved Novel Drugs

    It's been a busy year for the FDA.


    Bavencio packaging

    8. Bavencio (avelumab), EMD Serono Inc.

    Indications: A programmed death ligand-1 (PD-L1) blocking antibody indicated for patients 12 years and older with metastatic Merkel cell carcinoma (MCC). BAVENCIO is under accelerated approval, and continued approval will be contingent on further trials.

    Dosage: 10 mg/kg as an IVinfusion over 60 minutes every 2 weeks until disease progression or unacceptable toxicity. All patients should receive premedication with an antihistamine and acetaminophen prior to the first four infusions of avelumab. 

    Contraindications: None

    Read the FDA statement here

    Read the full prescribing information here

    Previous ButtonNext Button


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available